Covid19 Clinical Trial
Official title:
Prevalence Of COVID-19 Among Health-workers in a French General Hospital
The aim of this study is to evaluate the prevalence of COVID-19 among the workers of our hospital and the factors that are likely to influence this prevalence. It must be underlined that our hospital is settled in two towns and both hospital sites had different missions regarding the admissions of COVID-19-infected patients.
Since December 2019, the COVID-19 pandemic has widespread from China and put under strong
tension the health organizations throughout the world, especially since march 2020 in France.
As a consequence, the French hospitals had to cope with a massive amount of COVID-19 infected
patients and, thus, their organisations had to evolve in order to be able to admit more
patients in their critical care units.
First studies reported an important level of inter-human contagiousness of the SARS-CoV-2
virus with an "R0" (basic reproduction number) superior to 3, which could lead to a massive
contamination of healthcare workers since they are directly in charge of infected patients.
Other studies suggested that the healthcare workers are more likely to be contaminated by the
COVID-19 than the rest of the population, which pushed governments and hospital managers to
put in place individual and collective measures of protection in order to avoid nosocomial
transmissions and also to preserve the health of the hospital staffs in a context of high
tension on the hospital work force.
There are today few data about the contamination level among the healthcare workers of
general hospitals in France and about the severity of these contaminations. A national study
is being conducted but on a macroscopic regional scale. In addition to that, the proportion
of asymptomatic SARS-CoV-2 contaminated healthcare workers is not known as well as the origin
(hospital or community) of the contaminations.
In June 2020, the French Health Ministry decided to launch a collection of epidemiological
data in the French hospitals based on serologic tests. Thanks to this action and with the
results of all the RT PCR tests systematically conducted since the beginning of the pandemic
when a healthcare worker had COVID-19-like symptoms, the Centre Hospitalier Sud Essonne has
decided to conduct an observational study.
The aim of this study is to evaluate the prevalence of COVID-19 among the workers of our
hospital and the factors that are likely to influence this prevalence. It must be underlined
that our hospital is settled in two towns and both hospital sites had different missions
regarding the admissions of COVID-19-infected patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|